Since the establishment 42 years ago, CJ's biotechnology business has been giving efforts to develop products that fulfill everyone's desire for health by increasing product groups with its biotechnology represented by the mass fermentation technology and the wide variety of research in the pharmaceutical area.
CJ manufactured nucleic acids such as MSG (monosodium glutamate), IMP, GMP, and I&G starting with the production of condiments through the fermentation technology it developed for the first time in Korea in 1963. Also, it is playing a pivotal role in CJ's globalization through various activities such as the production of threonine and lysine, the growth promoter used with cattle feed in Indonesia, the place of the raw materials are produced, the exportation to European and American regions, and the establishment of plants in the place of raw material production. CJ is also giving much effort in strengthening R&D capacities such as it established a branch of Bio Research Center in Daejeon, the Mecca of bio-engineering and technology, to support technological development.
CJ started the pharmaceutical business in 1984, and it established a strong footing in the field as the company with strong research capabilities and potentials with the successful release of hepaccine, the vaccine for hepatitis-B. And now, it is growing into the world's leader in the pharmaceutical industry contributing to the healthy life of the patients in and out of the country with the continuous development of a variety of vaccines, cytokine, medicines for geriatric diseases, and antibiotics based on advanced bioengineering technology including the latest recombinant DNA technology.
The recent acquisition of Hanil Pharm reflected CJ's strong will to strengthen its capabilities in the pharmaceutical business with and gave CJ an opportunity to bring out the synergy in the sales and profit/loss areas and strengthen the overseas license network as Hanil Pharm has many original licenses for excellent foreign medicines such as Mevalotin, Bana, Herben, and Selbex.
CJ has laying the foundation for the development of the new products by making full use of the technological strength through the latest research facilities will continue to maintain its position as the leading company in the biotechnology and pharmaceutical areas in the growing global market through the know-how and the competitive strength with the price so that the customers can enjoy 'healthy' life and will lead the bio industry of the next generation by accelerating the development of environment-friendly biotechnical materials such as the microbiological products and biodegradable products.
| Contact Details: |
| 212 Carnegie Center, Suite 302 |
| Princeton |
| New Jersey |
| 08540 |
| United States of America |
| Tel: | 609 897 0780 |
| Fax: | 609 897 0725 |
| Email: | ajhorman@cj.net |
| WWW: | english.cj.net/index.html
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 5458 times since April 2007, the link to the organisation's website has been followed 446 times
Recent Search Terms used to find this page: CHEIL JEDANG CORP | cheil jedang | Cheil Jedang | cj cheil jedang | cheil jedang corporation | cheil jedang corporation | Cheil Jedang Corporation | cheil jedang corporation | CHEIL JEDANG | cj cheil jedang | .
Search for more companies in Princeton
Search for more companies in New Jersey
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Cheil Jedang Corporation - CJ Pharma
